* Warming tumours makes them more sensitive, study shows
* Technique uses electromagnetic energy to heat tissue
* Shares in BSD Medical, maker of system, more than double
(Adds detail on BSD Medical, shares)
By Kate Kelland
BERLIN, Sept 22 (Reuters) - Cancer patients whose tumours are targeted with heat treatment as well as chemotherapy are more likely to stay alive and cancer-free for longer than those who receive only chemotherapy, researchers said on Tuesday.
The finding suggests it may be possible to cut the dose of chemotherapy drugs by using heat, although more research is needed to establish this, they said.
German researchers looking at cancers in soft tissues such as muscle, fat and tissue around the joints, found that heat treatment more than doubled the proportion of patients whose tumours responded to chemotherapy.
Importantly, the process did not increase the harmful effects of chemotherapy treatment.
Shares in BSD Medical BSDM.O, which makes the heat treatment system used in the German study, more than doubled in early trade and were the biggest gainers on the Nasdaq market. The stock was 120 percent higher at $4.13 by 1350 GMT.
“We expect our findings will encourage other researchers to test the approach in other locally advanced cancers,” said Rolf Issels, a professor of medical oncology at the University of Munich in Germany.
“Targeted heat therapy has already shown promise in recurrent breast and locally advanced cervical cancer in combination with radiation, and studies combining it with chemotherapy in other localised tumours such as those in the pancreas and rectum are ongoing.”
Heat therapy for cancer involves a technique known as regional hyperthermia, which uses focused electromagnetic energy to warm the tissue in and around the tumour to between 40 and 43 degrees Celsius (104 to 109.4 degrees Fahrenheit).
The heat not only kills cancer cells, but also seems to make chemotherapy work better by making cancer cells more sensitive, Issels said. It also improves blood flow, allowing chemotherapy to be more effective.
Issels said his findings, presented at the ECCO-ESMO European cancer congress in Berlin, showed that soft tissue sarcoma patients receiving the targeted heat therapy plus chemotherapy “fared better on all outcome measurements”.
“Almost three years after starting treatment, they were 42 percent less likely to experience a recurrence of their cancer at the same site or to die than those who were getting chemotherapy alone,” he said.
The average length of time that patients remained disease free was 32 months in the group that got both treatments, compared with 18 months in the group that got chemotherapy alone — an improvement of 30 percent.
Issels said the equipment and specialist knowledge to be able to offer such heat therapies is only currently available in a handful of clinics and hospitals in Germany, the Netherlands, Switzerland, Norway and the United States.
But he urged cancer doctors to take note.
“The clear results of this trial show that the field has now matured to the point where we must step up efforts to explore its potential to offer an entirely new way of treating locally advanced disease in several major cancers,” he said. (Additional reporting by Ben Hirschler; editing by Lin Noueihed)